Imaging solid tumors using a targeted radioactive probe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of a radioactive probe, [68Ga]B7H3 Affibody-BCH, for PET imaging of solid tumors. It aims to evaluate the radioactive uptake of the probe and its correlation with B7-H3 receptor expression in tumor patients. The research utilizes whole-body PET technology to analyze the pharmacokinetic dynamics of the probe, establishing a framework for pharmacokinetic analysis in this context. The findings could enhance the understanding of tumor biology and improve imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age range 18-75 years, open to both male and female participants;
2. Participants must meet the following hematologic and hepatic/renal function criteria: Hematology: WBC ≥ 4.0 × 10\^9/L or neutrophils ≥ 1.5 × 10\^9/L, platelets ≥ 100 × 10\^9/L, hemoglobin ≥ 90 g/L; Prothrombin time (PT) or Activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal (ULN); Hepatic and renal functions: Total bilirubin (T-Bil) ≤ 1.5 times the upper threshold limit (ULT), ALT/AST ≤ 2.5 ULN or ≤ 5 ULT for subjects with liver metastasis, Alkaline phosphatase (ALP) ≤ 2.5 ULN (or ≤ 4.5 ULN in cases of bone or liver metastasis); Blood urea nitrogen (BUN) ≤ 1.5 × ULT, serum creatinine (SCr) ≤ 1.5 × ULT;
3. Normal cardiac function;
4. Expected survival of at least 12 weeks;
5. Good adherence to follow-up;
6. Presence of at least one measurable target lesion according to RECIST 1.1 criteria;
7. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;
8. Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;
9. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.

Exclusion Criteria:

1. Severe abnormalities in liver and renal function and blood counts;
2. Patients planning to conceive;
3. Pregnant or lactating women;
4. Individuals unable to lie flat for thirty minutes;
5. Individuals who refuse to participate in this clinical study;
6. Individuals suffering from claustrophobia or other psychiatric disorders;
7. Other situations deemed unsuitable for trial participation by the researchers.

Where it's running

• Xiangxi Meng
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• AKY-2519 (B7‑H3 targeted radioligand) for metastatic castration‑resistant prostate cancer

  This trial tests whether AKY‑2519, a B7‑H3–targeted radioactive medicine used for imaging and treatment, is safe and can shrink tumors in men with metastatic castration‑resistant prostate cancer, including those who have had prior 177Lu‑PSMA‑617.

  Recruiting at 8 sites Phase 1 Aktis Oncology, Inc. · Irvine, California and 7 other locations · NCT07581184

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• Local methylene blue injection around the pelvis to help avoid leakage after rectal cancer surgery

  This study tests whether injecting a diluted methylene blue around the pelvic area after rectal cancer surgery can reduce leakage and help avoid a permanent stoma in high-risk patients.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT07833319

• 18F-grazy-02 PET/CT to monitor immune therapy in cancer

  This study tests whether 18F-grazy-02 PET/CT can safely monitor immune therapy in people with lymphoma or solid tumors being treated with immune checkpoint inhibitors or CAR-T cells.

  Recruiting Phase 1/2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT07724535

• Firmonertinib given before surgery for EGFR-mutated NSCLC

  This study tests whether taking firmonertinib before and around surgery helps patients with resectable EGFR-mutated NSCLC see more tumor shrinkage before the operation.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07622706

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.